Posts tagged animal studies
Roth starts Arch Therapeutics at buy

Roth Capital Partners initiated coverage of Arch Therapeutics (OTC:ARTH) with a ‘buy” rating and $3 price target. The stock closed at 66 cents on Feb. 13.

Read More
Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”.

The composition of matter patent protects the use of Can-Fite’s proprietary A3 Adenosine Receptor (A3AR) modulator, including the preparation of its pharmaceutical compositions and its use in patients across all therapeutic indications.

Read More